Compare Stocks: TNYA, KYTX, EBS, and CAPR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$8.93 +8.4%	$8.10	$2.96 ▼ $40.37	$519.19M	0.8	3.13 million shs	6.37 million shs
EBS Emergent Biosolutions	$5.91 -5.5%	$6.52	$4.36 ▼ $14.06	$302.80M	2.37	986,101 shs	2.18 million shs
KYTX Kyverna Therapeutics	$5.16	$6.78	$5.02 ▼ $13.67	$319.09M	2.12	913,050 shs	973,919 shs
TNYA Tenaya Therapeutics	$0.37 +2.7%	$0.56	$0.35 ▼ $1.56	$84.31M	2.88	3.46 million shs	1.60 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	+13.81%	+35.08%	-7.93%	+109.67%	+35.75%
EBS Emergent Biosolutions	-2.80%	-6.06%	-1.28%	-17.35%	-40.43%
KYTX Kyverna Therapeutics	-1.15%	-8.35%	-17.04%	-32.46%	-25.00%
TNYA Tenaya Therapeutics	-0.19%	-10.24%	-36.13%	-54.08%	-74.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$8.93 +8.4%	$8.10	$2.96 ▼ $40.37	$519.19M	0.8	3.13 million shs	6.37 million shs
EBS Emergent Biosolutions	$5.91 -5.5%	$6.52	$4.36 ▼ $14.06	$302.80M	2.37	986,101 shs	2.18 million shs
KYTX Kyverna Therapeutics	$5.16	$6.78	$5.02 ▼ $13.67	$319.09M	2.12	913,050 shs	973,919 shs
TNYA Tenaya Therapeutics	$0.37 +2.7%	$0.56	$0.35 ▼ $1.56	$84.31M	2.88	3.46 million shs	1.60 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	+13.81%	+35.08%	-7.93%	+109.67%	+35.75%
EBS Emergent Biosolutions	-2.80%	-6.06%	-1.28%	-17.35%	-40.43%
KYTX Kyverna Therapeutics	-1.15%	-8.35%	-17.04%	-32.46%	-25.00%
TNYA Tenaya Therapeutics	-0.19%	-10.24%	-36.13%	-54.08%	-74.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	2.27	Hold	$30.25	248.98% Upside
EBS Emergent Biosolutions	2.17	Hold	$10.00	71.38% Upside
KYTX Kyverna Therapeutics	2.86	Moderate Buy	$29.00	463.65% Upside
TNYA Tenaya Therapeutics	2.86	Moderate Buy	$4.00	986.96% Upside

Current Analyst Ratings Breakdown

Latest TNYA, KYTX, EBS, and CAPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/26/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/22/2026	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/8/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
9/25/2026	KYTX Kyverna Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$25.00
9/25/2026	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/25/2026	KYTX Kyverna Therapeutics	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/23/2026	KYTX Kyverna Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/21/2026	KYTX Kyverna Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/17/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$5.00 ➝ $21.00
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$5.00 ➝ $21.00

(Data available from 11/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$22.27M	22.63	N/A	N/A	$5.53 per share	1.57
EBS Emergent Biosolutions	$742.90M	0.40	$3.32 per share	1.76	$9.95 per share	0.59
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$3.85 per share	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$0.57 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
EBS Emergent Biosolutions	$52.60M	-$3.55	N/A	7.89	N/A	-40.16%	-0.40%	-0.15%	N/A
KYTX Kyverna Therapeutics	-$161.31M	-$2.94	N/A	N/A	N/A	N/A	-81.92%	-63.74%	11/11/2026 (Estimated)
TNYA Tenaya Therapeutics	-$90.60M	-$0.53	N/A	N/A	N/A	N/A	-83.75%	-66.53%	11/11/2026 (Estimated)

Latest TNYA, KYTX, EBS, and CAPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	KYTX Kyverna Therapeutics	-$0.68	N/A	N/A	N/A	N/A	N/A
11/11/2026	Q3 2026	TNYA Tenaya Therapeutics	-$0.10	N/A	N/A	N/A	$0.80 million	N/A
11/9/2026	Q3 2026	CAPR Capricor Therapeutics	-$0.1278	N/A	N/A	N/A	$41.71 million	N/A
11/2/2026	Q3 2026	EBS Emergent Biosolutions	-$0.3914	-$0.36	+$0.0314	-$0.64	$123.22 million	$110.00 million
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/11/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.6783	-$0.63	+$0.0483	-$0.63	N/A	N/A
8/5/2026	Q2 2026	EBS Emergent Biosolutions	-$0.0850	$0.60	+$0.6850	-$3.49	$177.50 million	$234.30 million
8/5/2026	Q2 2026	TNYA Tenaya Therapeutics	-$0.0683	-$0.20	-$0.1317	-$0.20	$10.00 million	$1.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	7.35	7.35
EBS Emergent Biosolutions	1.70	5.42	2.95
KYTX Kyverna Therapeutics	0.15	9.06	9.06
TNYA Tenaya Therapeutics	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
EBS Emergent Biosolutions	78.40%
KYTX Kyverna Therapeutics	18.08%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	9.20%
EBS Emergent Biosolutions	6.00%
KYTX Kyverna Therapeutics	17.60%
TNYA Tenaya Therapeutics	2.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	231	58.14 million	52.79 million	Optionable
EBS Emergent Biosolutions	900	51.27 million	48.20 million	Optionable
KYTX Kyverna Therapeutics	149	61.84 million	50.96 million	Optionable
TNYA Tenaya Therapeutics	70	227.93 million	221.80 million	Optionable

TNYA, KYTX, EBS, and CAPR Headlines

Recent News About These Companies

Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

1 hour ago | globenewswire.com

Tenaya Therapeutics (TNYA) Set to Release Earnings on Wednesday

November 4 at 9:25 AM | marketbeat.com

Tenaya Therapeutics (TNYA) Gets a Buy from Piper Sandler

October 31, 2026 | theglobeandmail.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Has Consensus Target Price of $4.00

October 25, 2026 | americanbankingnews.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Has Average Target Price of $4.00 According to Analysts

October 25, 2026 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) and C4 Therapeutics (NASDAQ:CCCC) Financial Survey

October 22, 2026 | defenseworld.netD

Tenaya Therapeutics Announces RMAT Designation To TN-401

September 14, 2026 | rttnews.com

Tenaya's TN-401 Receives FDA RMAT Status For PKP2-Associated Cardiomyopathy; Stock Up

September 14, 2026 | rttnews.com

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular ...

September 14, 2026 | finance.yahoo.com

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

September 14, 2026 | globenewswire.com

Tenaya op H.C. Wainwright-conferentie: gentherapiedata

September 11, 2026 | nl.investing.com

Tenaya Therapeutics Corporate Event Calendar | NASDAQ:TNYA

September 11, 2026 | benzinga.com

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

September 3, 2026 | globenewswire.com

Faraz Ali Sells 22,232 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

August 18, 2026 | insidertrades.com

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

August 14, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Viridian Therapeutics (VRDN)

August 7, 2026 | theglobeandmail.com

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026 | globenewswire.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 4, 2026 | globenewswire.com

Cours Tenaya Therapeutics, Inc.

July 29, 2026 | zonebourse.comZ

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 14, 2026 | globenewswire.com

Tenaya Therapeutics (TNYA) Slides to $0.86 as Bearish Pressure Tests Support - Order Block

July 13, 2026 | donanimhaber.comD

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, KYTX, EBS, and CAPR Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

$8.93 +0.69 (+8.37%)

Closing price 04:00 PM Eastern

Extended Trading

$8.94 +0.01 (+0.06%)

As of 05:15 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Emergent Biosolutions NYSE:EBS

$5.91 -0.34 (-5.50%)

Closing price 03:59 PM Eastern

Extended Trading

$5.89 -0.02 (-0.27%)

As of 05:03 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Kyverna Therapeutics NASDAQ:KYTX

$5.16 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$5.21 +0.05 (+0.99%)

As of 05:11 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Tenaya Therapeutics NASDAQ:TNYA

$0.37 +0.01 (+2.66%)

Closing price 04:00 PM Eastern

Extended Trading

$0.38 +0.01 (+3.81%)

As of 05:15 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNYA, KYTX, EBS, and CAPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNYA, KYTX, EBS, and CAPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNYA, KYTX, EBS, and CAPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, KYTX, EBS, and CAPR Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

Emergent Biosolutions NYSE:EBS

Kyverna Therapeutics NASDAQ:KYTX

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNYA, KYTX, EBS, and CAPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNYA, KYTX, EBS, and CAPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNYA, KYTX, EBS, and CAPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, KYTX, EBS, and CAPR Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

Emergent Biosolutions NYSE:EBS

Kyverna Therapeutics NASDAQ:KYTX

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools